<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01153503</url>
  </required_header>
  <id_info>
    <org_study_id>022010-002</org_study_id>
    <nct_id>NCT01153503</nct_id>
  </id_info>
  <brief_title>Ultrasound-guided Transversus Abdominis Plane Block After Hysterectomy</brief_title>
  <acronym>TAP</acronym>
  <official_title>Ultrasound-guided Transversus Abdominis Plane Block After Abdominal Hysterectomy: a Prospective Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this randomized, controlled, observer-blinded study we plan to evaluate ultrasound-guided
      transversus abdominis plane (TAP) block for postoperative pain management in patients
      undergoing abdominal hysterectomy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients undergoing abdominal hysterectomy (n=75) at Parkland Hospital will be randomized
      into one of three groups to receive either ultrasound-guided bilateral TAP block with or
      without NSAIDs and acetaminophen (Groups 1 and 2) or the conventional analgesic regimen
      (Group 3) for postoperative pain management. The remaining aspect of perioperative care,
      including the general anesthetic technique, will be standardized and similar for all
      patients. The duration of the involvement in the study will be until 48 hours
      postoperatively. The pre-anesthesia care unit personnel will identify patients during their
      preoperative clinic visit. There will be no incentive or payment to the patients.

      Patients in Group 1 and 2 will receive ultrasound-guided bilateral TAP block after surgery.
      In the first 24-h postoperative period, patients in Groups 1 and 3 will receive acetaminophen
      650 mg every 6 h orally, ketorolac 30 mg every 6 h, and morphine via an intravenous patient
      controlled analgesia (IV-PCA) system to maintain adequate pain control. Patients in Group 2
      will receive IV-PCA morphine for the first 24 hours in addition to the ultrasound-guided
      bilateral block. In the 24-48 h study period, all patients will receive oral ibuprofen 800 mg
      three times a day and a combination of hydrocodone/acetaminophen 5mg/500 mg 1-2 tablets every
      6h, prn. The postoperative analgesia will be documented using the visual analog score (0=no
      pain,10=worst pain). In addition, total opioid dose over the 48-h study period will be
      documented. Postoperative nausea will be measured using a categorical scoring system (none=0,
      mild=1, moderate=2, severe=3) and episodes of vomiting will be documented. Rescue antiemetics
      will be given to any patient who complains of nausea or vomiting. All variables will be
      assessed at 2, 6, 12, 24, and 48 hours, postoperatively by an investigator blinded to group
      allocation.

      Primary endpoint will be in about 24 hours after surgery morphine consumption. The secondary
      endpoints will include the VAS pain score at 6, 12, 24 and 48 hours after surgery and side
      effects associated with morphine use.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Morphine Consumption</measure>
    <time_frame>24 hours post surgery</time_frame>
    <description>Morphine consumption over the first 24 hours</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Post Operative Pain</condition>
  <arm_group>
    <arm_group_label>Ketorolac 30 mg, IV + TAP block</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ketorolac 30 mg, IV + Bilateral ultrasound-guided TAP blocks at the end of the surgery
First 24-h Postoperative: Ketorolac 30 mg q 6h + acetaminophen 650 mg q6h + IV-PCA morphine
24-48-h Postoperative: Oral ibuprofen 800 mg q 8 h + hydrocodone/acetaminophen 5mg/500 mg 1-2 tablets q 6h, prn</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TAP block</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intraoperative (at the end of surgery): Bilateral ultrasound-guided TAP block at the end of the surgery
First 24-h Postoperative: IV-PCA morphine
24-48-h Postoperative: Oral ibuprofen 800 mg q 8 h + hydrocodone/acetaminophen 5mg/500 mg 1-2 tablets q 6h, prn</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketorolac 30 mg</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Intraoperative (at the end of surgery): Ketorolac 30 mg, IV at the end of the surgery.
First 24-h Postoperative: Ketorolac 30 mg q 6h + acetaminophen 650 mg q6h +IV-PCA morphine.
24-48-h Postoperative: Oral ibuprofen 800 mg q 8 h + hydrocodone/acetaminophen 5mg/500 mg 1-2 tablets q 6h, prn</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TAP block</intervention_name>
    <description>Group Intraoperative (at the end of surgery): Ketorolac 30 mg, IV + TAP block; TAP block
First 24-h Postoperative: Ketorolac 30 mg q 6h + acetaminophen 650 mg q6h + IV-PCA morphine
24-48-h Postoperative: Oral ibuprofen 800 mg q 8 h + hydrocodone/acetaminophen 5mg/500 mg 1-2 tablets q 6h, prn</description>
    <arm_group_label>Ketorolac 30 mg, IV + TAP block</arm_group_label>
    <arm_group_label>TAP block</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-80 years old

          -  Female ASA physical status 1-3 scheduled for abdominal hysterectomy

          -  Able to participate personally or by legal representative in informed consent in
             English or Spanish

        Exclusion Criteria:

          -  History of relevant drug allergy

          -  Age less than 18 or greater than 80

          -  Chronic opioid users who may have a tolerance to opioids

          -  Psychiatric disturbance

          -  Inability to understand the study protocol procedures

          -  Patient refusal
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Irina Gasanova, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas Southwestern Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UTSW Parkland Health Hospital System</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 28, 2010</study_first_submitted>
  <study_first_submitted_qc>June 29, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2010</study_first_posted>
  <results_first_submitted>March 18, 2014</results_first_submitted>
  <results_first_submitted_qc>March 18, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 22, 2014</results_first_posted>
  <last_update_submitted>January 31, 2018</last_update_submitted>
  <last_update_submitted_qc>January 31, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Texas Southwestern Medical Center</investigator_affiliation>
    <investigator_full_name>Irina Gasanova</investigator_full_name>
    <investigator_title>ASSOC PROFESSOR</investigator_title>
  </responsible_party>
  <keyword>Postoperative pain, TAP block, Hysterectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Morphine</mesh_term>
    <mesh_term>Hydrocodone</mesh_term>
    <mesh_term>Acetaminophen, hydrocodone drug combination</mesh_term>
    <mesh_term>Oxycodone</mesh_term>
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Ibuprofen</mesh_term>
    <mesh_term>Ketorolac</mesh_term>
    <mesh_term>Ketorolac Tromethamine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ketorolac 30 mg, IV + TAP Block</title>
          <description>Bilateral ultrasound-guided TAP blocks and Ketorolac 30 mg IV at the end of the surgery
First 24-h Postoperative: Ketorolac 30 mg q 6h + acetaminophen 650 mg q6h and IV-PCA morphine
24-48-h Postoperative: Oral ibuprofen 800 mg q 8 h + hydrocodone/acetaminophen 5mg/500 mg 1-2 tablets q 6h, prn</description>
        </group>
        <group group_id="P2">
          <title>TAP Block</title>
          <description>Bilateral ultrasound-guided TAP block at the end of the surgery
First 24-h Postoperative: IV-PCA morphine
24-48-h Postoperative: Oral ibuprofen 800 mg q 8 h + hydrocodone/acetaminophen 5mg/500 mg 1-2 tablets q 6h, prn</description>
        </group>
        <group group_id="P3">
          <title>Ketorolac 30 mg</title>
          <description>Ketorolac 30 mg, IV at the end of surgery
First 24-h Postoperative: Ketorolac 30 mg q 6h + acetaminophen 650 mg q6h + IV-PCA morphine 24-48-h Postoperative: Oral ibuprofen 800 mg q 8 h + hydrocodone/acetaminophen 5mg/500 mg 1-2 tablets q 6h, prn</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ketorolac 30 mg, IV + TAP Block</title>
          <description>Bilateral ultrasound-guided TAP block at the end of the surgery
First 24-h postoperative: Ketorolac 30 mg, IV, every 6h + acetaminophen 650 mg, orally, every 6h + IV-PCA morphine</description>
        </group>
        <group group_id="B2">
          <title>TAP Block</title>
          <description>Bilateral ultrasound-guided TAP block at the end of the surgery+ IV-PCA morphine
First 24-h postoperative: IV-PCA morphine</description>
        </group>
        <group group_id="B3">
          <title>Ketorolac 30 mg IV</title>
          <description>Ketorolac 30 mg, IV at the end of surgery
First 24-h postoperative: Ketorolac 30 mg q 6h + acetaminophen 650 mg q6h + IV-PCA morphine</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
            <count group_id="B2" value="24"/>
            <count group_id="B3" value="25"/>
            <count group_id="B4" value="74"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.4" spread="5.4"/>
                    <measurement group_id="B2" value="43.8" spread="6.5"/>
                    <measurement group_id="B3" value="43.1" spread="5.6"/>
                    <measurement group_id="B4" value="43.1" spread="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="74"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Morphine Consumption</title>
        <description>Morphine consumption over the first 24 hours</description>
        <time_frame>24 hours post surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketorolac 30 mg, IV + TAP Block</title>
            <description>Bilateral ultrasound-guided TAP block at the end of the surgery
First 24-h postoperative: Ketorolac 30 mg, IV, every 6h + acetaminophen 650 mg, orally, every 6h + IV-PCA morphine</description>
          </group>
          <group group_id="O2">
            <title>TAP Block</title>
            <description>Bilateral ultrasound-guided TAP block at the end of the surgery+ IV-PCA morphine
First 24-h postoperative: IV-PCA morphine</description>
          </group>
          <group group_id="O3">
            <title>Ketorolac 30 mg</title>
            <description>Ketorolac 30 mg after surgery
First 24-h postoperative: Ketorolac 30 mg q 6h + acetaminophen 650 mg q6h + IV-PCA morphine</description>
          </group>
        </group_list>
        <measure>
          <title>Morphine Consumption</title>
          <description>Morphine consumption over the first 24 hours</description>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.4" spread="25.7"/>
                    <measurement group_id="O2" value="38.6" spread="26.8"/>
                    <measurement group_id="O3" value="42.6" spread="31.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>48-hour study period after surgery</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ketorolac 30 mg, IV + TAP Block</title>
          <description>Bilateral ultrasound-guided TAP block at the end of the surgery
First 24-h postoperative: Ketorolac 30 mg, IV, every 6h + acetaminophen 650 mg, orally, every 6h + IV-PCA morphine</description>
        </group>
        <group group_id="E2">
          <title>TAP Block</title>
          <description>Bilateral ultrasound-guided TAP block at the end of the surgery+ IV-PCA morphine
First 24-h postoperative: IV-PCA morphine</description>
        </group>
        <group group_id="E3">
          <title>Ketorolac 30 mg</title>
          <description>Ketorolac 30 mg after surgery
First 24-h postoperative: Ketorolac 30 mg q 6h + acetaminophen 650 mg q6h + IV-PCA morphine</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Irina Gasanova, MD, PhD</name_or_title>
      <organization>University of Texas Southwestern Medical Center</organization>
      <phone>214-590-0064</phone>
      <email>Irina.Gasanova@UTSouthwestern.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

